~~<i id='43E1BD7A6E'><strike id='43E1BD7A6E'><tt id='43E1BD7A6E'><pre id='43E1BD7A6E'></pre></tt></strike></i>~~

Home» explore» fashion

fashion

author：entertainment 2025-09-30 08:01:06 Page View：69368

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What Kate Middleton's cancer revelation might teach the world
Next article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Wikipedia

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

Cancer, immunology, HIV research ensnared in fetal tissue politics

MollyFergusonforSTATScientistsattheUniversityofWisconsin-Madisonhavespentyearstryingtounravelthedeta

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Orchard's therapy for neuron disease in children wins FDA approval

AdobeTheFoodandDrugAdministrationonMondayapprovedagenetherapyformetachromaticleukodystrophy,adevasta